Summary: In a prospective study, 254 of 5649 unselected patients scheduled for surgery at our hospital were identified preoperatively as having either acquired (n=182) or inherited (n=72) impaired primary hemostasis (platelet dysfunction including von Willebrand disease). All patients were initially pretreated with desmopressin (DDAVP). Response to DDAVP or subsequent treatment(s) was defined as correction of any one of the abnormal PFA-100 platelet function tests. The non-responders were additionally treated with tranexamic acid or aprotinin; those with von Willebrand disease (vWD) received factor VIII concentrates with von Willebrand factor (vWF). Those still unresponsive to therapy received conjugated estrogens and, as a last attempt, a platelet transfusion. The administration of DDAVP led to a correction of platelet dysfunction in 229 of the 254 patients treated (90.2%). Tranexamic acid was effective in 12 of 16, aprotinin in 3 of 5, and factor VIII concentrates with vWF in all 4 pa-of vasopressin (8) (9) (10) (11) (12) (13) (14) (15) (16) , has been shown to reduce blood loss and the need for blood transfusion in selected groups of surgical patients at an increased risk of bleeding due to platelet dysfunction. Aprotinin (17, 18) , tranexamic acid, εaminocaproic acid (19, 20) , and premarin (a mixture of conjugated estrogens) (21) are less commonly used in these indications. However, there still is no validated concept of when to use these drugs or how to assess their effects before or during a surgical intervention.
The platelet function analyzer (PFA-100) has proven to be a reliable device for in vitro measurement of platelet adhesion and aggregation (22) (23) (24) (25) (26) (27) . In the first part of this prospective study, the PFA-100 enabled us to identify all patients with impaired primary hemostasis. This led to several questions, e.g., whether treatment was necessary and, if so, how preoperative correction of the defect should be carried out, and whether the patient would benefit from such prophylactic treatment.
METHODS
The study was approved by the local ethics committee, and informed consent was obtained from each participant. A total of 5649 (2631 females and 3018 males, ranging in age between 17 and 87 years) patients scheduled for elective general with vascular, thoracic, orthopedic, gy-necology, urology, rhinolaryngology with headneck or cranio-maxillofacial surgery were recruited in the study from January 2, 2000 to January 2, 2001. Emergency surgeries and patients with pre-existing hemostatic disorders and anticoagulation therapies were excluded. A total of 256 from 5649 unselected patients (Table 1) were preoperatively identified to have impaired hemostasis. On entry, hemostatic screening including packed cells (PC), activated partial thromboplastin time (aPTT), and prothrombin time (PT) was done as a part of the preoperative tests ordered by the surgeons and/or anesthesiologists. Additionally, each patient had a complete history and physical examination by the anesthesiologist. The primary hemostasis was assessed by the PFA-100: collagen-epinephrine; Collagen-ADP (Dade-Behring, Schwalbach, Germany).
The PFA-100 device simulates primary hemostasis by aspirating citrate-anticoagulated whole blood (3.2%; 106 mM) and high shear (5000-6000/sec) through a 150-µm aperture membrane coated with collagen and either adenosine diphosphate (ADP) or epinephrine (22) . The reference range of PFA-100: collagenepinephrine was 82 to 150 sec. The collagen-ADP test had a reference range between 62 and 100 seconds. The variation coefficient for collagenepinephrine was 5.9% from day to day (same proband) compared to 5.7%, respectively, for collagen-ADP. Additionally, the bleeding time (Surgicutt, New Jersey) was performed before and after preoperative anti-bleeding drug administration.
Von Willebrand factor (vWF): Ag was measured using the particle immunoassay (STA LI-ATEST vWF, Boehringer Mannheim, Germany). The cut-off used to define abnormal and suspected vWF values were < 50% and 50%-70%, respectively. The vWF multimeric analyses were performed in the follow-up period according to a luminographic procedure (28) . The classification followed the guidelines published by the "Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis" (29) .
All patients with impaired primary hemostasis (congenital, vWD, or acquired platelet dysfunctions, and combined hemostatic defects, e.g. liver cirrhosis) were preoperatively treated with a 30minute infusion of 0.3 µg/kg DDAVP (Minirin ® ). Platelet function was subsequently re-assessed based on the PFA-100 parameters and bleeding time. Response to DDAVP or subsequent treatment(s) was defined as correction of any one of the abnormal PFA-100 platelet function tests. All responders immediately underwent surgery while continuing hemostatic treatment with the same drug (Table 2) . vWD patients who did not respond to DDAVP were treated with a factor VIII concentrate containing vWF (Hemate HS ® ). All other non-responders were treated with either aprotinin (Trasylol ® ) or tranexamic acid (Ugurol ® ). If one of the PFA-100 cartridges remained abnormal, platelet transfusion and/or conjugated estrogens (Premarin ® ) were the last therapeutic attempt in the remaining cases.
The statistical analysis of non-normally distributed random samples was performed using the Mann-Whitney test (30) . The level of significance was defined as p<0.05 (StatView Program 4.5). A Fisher exact test was used to compare the frequency of transfusion and costs of treatment in the different groups of patients (30, 31) . When all the single values are known, the Bayes theorem can be used to calculate the positive predictive value for "blood transfusions" out of a combination of the different variables. This study fulfills the conditions for the Bayes theorem, namely, independence of the individual tests and application of the tests in parallel (30) . 
RESULTS
Impaired hemostasis was detected in 256 of 5649 patients. The results of hemostatic testing used are summarized in Table 3 . The hemostatic defect was most frequently identified based on collagen-epinephrine (97.7%) and followed by collagen-ADP (77.7%). These 2 screening tests for primary hemostasis showed significant differences in the medians for the patients with impaired (primary) hemostasis compared with patients without impaired hemostasis. In contrast, none of the routine tests revealed any significant differences.
We preoperatively identified 254 of 5649 unselected patients scheduled for surgery at our hospital as having either acquired (n=182) or inherited (n=72) impaired primary hemostasis (platelet dysfunction including von Willebrand disease) ( Fig. 1 ). Only 2 patients (0.8%) had a secondary (plasmatic) hemostatic disorder (congenital dysfibrinogenemia and factor VII deficiency), which were treated with fibrinogen concentrate (Fibrogammin HS ® ) and F VII concentrate (FAKTOR VII S-TIM 4 ® ). In the remaining patients, platelet dysfunction was due to an acquired or hereditary thrombopathy, and vWD. In this group, DDAVP administration resulted in correction of platelet dysfunction in 229 of 254 patients (90.2%), as demonstrated by collagenepinephrine and, to a lesser degree, by collagen-ADP (n=170; 66.9%) or bleeding time (n=153; 60.2%). The greatest effect of DDAVP was observed in patients with vWD (92.6%) followed by platelet dysfunction due to the use of nonsteroidal anti-inflammatory drugs (acetylsalicylic acid, diclofenac, ibuprofen, piroxicam) (92.4%) or antibiotics (ciprofloxacin, benzylpenicillin, ce- fotaxime, azlocillin) (90%), and platelet dysfunction due to liver cirrhosis (84.6%), inherited thrombopathies (83.3%), or uremia (42.9%). In 2 cases, the correction of platelet dysfunction was detectable by collagen-ADP but not by collagen-epinephrine (Table 4 ). The effect of the other drugs in patients unresponsive to DDAVP was variable ( Table 5 ). It is unclear why some patients respond to a drug (e.g., acetylsalicylic acid) while others do not. Tranexamic acid was effective in 12 of 16, aprotinin in 3 of 5, and factor VIII concentrates with vWF in all 4 patients unresponsive to DDAVP. The remaining 6 patients were pretreated with conjugated estrogens, and 2 of these patients were additionally treated with platelet transfusion (Fig. 2) . This led only in part to correction of platelet function as determined by the PFA-100: collagen-epinephrine (288 seconds before and 197 seconds after platelet transfusion).
Significant side effects occurred in only 3 isolated cases. Anaphylaxis developed in 1 patient after aprotinin administration. Hyponatremia developed in 1 patient treated with DDAVP, and cerebral convulsions developed in 1 patient with a history of epilepsy. All 3 patients recovered without complications. In addition, mild flushing developed in 54 patients after the first dose of DDAVP.
Only transfusions during surgery or postoperative transfusions were included for all groups. Preoperative correction of platelet dysfunction was found to reduce the need for homologous blood transfusion in almost all cases. The frequency of blood transfusion was lower, but not statistically significant (9.4% vs. 12.2%: doublesided Fisher exact test, p = 0.202) in preoperatively treated patients with impaired primary hemostasis than in patients without impaired primary hemostasis (Fig. 3) . In a retrospective similar group at the same hospital in 1999 (Table 6 ), we preoperatively identified 317 of 5102 unselected patients scheduled for surgery at our hospital as having either acquired (n=299) or inherited (n=18) impaired primary hemostasis (platelet dysfunction including von Willebrand disease) (Fig. 4) . The frequency of blood transfusion was statistically significant higher (double-sided Fisher exact test, p < 0.001) in patients without preoperative correction of impaired primary hemostasis (Fig. 3) . A total of 311 patients with impaired hemostasis (n=317) exhibited abnormal PFA-100: collagenepinephrine (Table 7) , and the majority of these patients (n=283; 89.3%) received blood transfusions ( Fig. 4, Table 7 ). Both PFA-100 tests showed normal platelet function in the remaining patients (n=4785).
Based on these data (retrospective group), the calculated specifity and sensitivity for blood transfusion were 99.3% and 33.9% for the PFA-100: collagen-epinephrine, compared to 99.4% and 19.9% for the PFA-100: collagen-ADP, respectively. The prevalence for blood transfusion was 16.15% (824 of 5102 patients). Thus, the positive and negative predictive values for blood transfusions were 91.7% and 89.6% for the PFA-100: collagen-epinephrine, compared to 86.5% and 86.6% for the PFA-100: collagen-ADP, respectively.
DISCUSSION
The objective of this study was to design a concept for prophylactic correction of acquired and congenital platelet dysfunctions capable of causing significant bleeding during surgical interventions. We succeeded in normalizing the hemostatic defect in nearly all patients studied. Conditions associated with plasmatic defects were corrected by administration of fibrinogen and factor VII; the 2 patients affected had congenital dysfibrinogenemia and factor VII deficiency. The remaining patients had acquired (more common) or inherited (less common) platelet dysfunctions that could be corrected by DDAVP in almost all cases (90.2%). In agreement with the findings in the literature (8) (9) (10) (11) (12) (13) (14) (15) (16) (32) (33) (34) , 84% to 100% of our patients responded to DDAVP ( Table 4 ). The small number of cases studied may be the reason for the low response observed in certain cases (e.g., uremic patients or those receiving benzylpenicillin). It is still unclear whether DDAVP may also help in the treatment of patients with thrombasthenia or Bernard-Soulier syndrome; the 2 such patients in our group were unresponsive. Interestingly, the majority of non-responders to DDAVP did respond to aprotinin, tranexamic acid, or conjugated estrogens. Only 2 patients required platelet transfusions; both of these patients had liver cirrhosis. The reason for our preferential use of DDAVP over aprotinin or tranexamic acid is the high cost of aprotinin and the relatively high frequency of severe side effects of both drugs. Adverse reactions to DDAVP are usually mild, whereas those related to the other 2 drugs can be dangerous (35, 36) . In this study, a relatively large number of patients treated with DDAVP experienced facial flushing, 1 experienced hyponatremia, and 1 with a history of epilepsy had an epileptic seizure. In comparison, side effects did not develop in any of the 16 patients treated with tranexamic acid, whereas significant adverse reactions developed in 2 of the 5 patients treated with aprotinin. Because the effect of tranexamic acid and aprotinin on platelet dysfunction seems to be comparable to that of DDAVP, these drugs can all be used at the discretion of the attending physician based on his or her experience.
The effects of DDAVP, aprotinin, and tranexamic acid could be detected within 30 minutes of administration, whereas conjugated estrogens required 15 to 30 minutes to take effect. DDAVP may lead to improvement of hemostasis by increasing the levels of coagulation factor VIII, vWF, and tissue plasminogen activator (8) . However, the mechanism by which aprotinin, tranexamic acid, and conjugated estrogens influence platelet function remains somewhat unclear. There is evidence showing that aprotinin and tranexamic acid may increase the expression of GP Ib-receptor on platelets, thereby improv- ing platelet adhesion (16, 17, 19, 36) . Conjugated estrogens also seem to increase platelet aggregation (37, 38) . The improvement of platelet function by these drugs was confirmed by the functional assays, particularly the collagen-epinephrine test. It seems very likely that patients who receive glycoprotein IIb/IIIa inhibitors can be assessed in the same manner. In 2 cases not included in the present study, DDAVP also led to correction of platelet dysfunction as determined by the PFA-100 collagen-epinephrine test. However, further studied are needed to confirm these findings. Although this study does not have data from a prospective control group for comparison, correction of the hemostatic defects was found to decrease the need for blood transfusion dramatically. The frequency of blood transfusions did not differ significantly among the groups of patients, but was lower in preoperatively treated patients with platelet dysfunctions than in their untreated counterparts (Fig. 3) . The best positive and negative predictive values for blood transfusion were reflected by the PFA-100: collagen-epinephrine (91.7% and 89.6%).
Although the comparison between the prospective and retrospective groups is fraught with some problems, this study indubitably raises some crucial questions that must be clearly answered before a final conclusion can be drawn. The first question is related to the additional costs of the whole monitoring. Taking into account all hemostatic screening tests, hemostatic treatments, and blood transfusions, the additional costs remained within reasonable limits. While the total costs were approximately $220 (£190) for each patient without impaired hemostasis, they increased to roughly $390 (£340) for each patient requiring hemostatic treatment for platelet dysfunction. However, the latter patients required fewer blood transfusions than they would have without hemostatic treatment. The second and most important question is whether this preoperative treatment regimen was justified in these patients, or in all surgical patients with impaired hemostasis. Although we tried to treat only those patients requiring "major" surgery, i.e. surgery associated with a significant blood loss, we do not recommend the generalized use of this regimen at present. It must be emphasized that the main aim of this study was to determine the best way to identify patients at risk of bleeding and, if treatment was indicated, how to optimally treat these patients preoperatively and perioperatively. Many studies have already addressed this question, but only in certain subgroups of patients, i.e. those requiring cardiosurgery and/or those lacking sufficient laboratory monitoring (11, 13, 15, 17, 18, 39) . This study included all groups of surgical patients as well as most causes of platelet dysfunction. In addition, we tried to find out which patients may or may not respond to the available drugs. Our findings did not permit a clear determination of which patients will exhibit primary refractoriness to the drugs. Therefore, we recommend initial treatment with DDAVP and second-line treatment with the other drugs as indicated.
Last but not least, the answer to the question of whether transient withdrawal of the causative drug might be an alternative to treatment with hemostatic agents seems to be "yes." However, withdrawal of the drug is not feasible in the majority of cases, either because of the severity of the underlying disease (e.g., coronary artery disease) or because the patients have to be discharged from the hospital as long as the platelet dysfunction persists. Thus, all factors must be considered before making a decision to perform such prophylactic treatment. 
